Public Firm Sonnet BioTherapeutics to Launch HyperLiquid Treasury in New Deal
Sonnet BioTherapeutics, Inc. has agreed to merge with Rorschach I LLC to become Hyperliquid Strategies in a deal worth $888 million.
Sonnet BioTherapeutics, Inc. has agreed to merge with Rorschach I LLC to become Hyperliquid Strategies in a deal worth $888 million.